Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Q-Linea

24.10 SEK

-1.87 %

Less than 1K followers

QLINEA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.87 %
-2.15 %
-49.38 %
-46.68 %
-73.57 %
-85.05 %
-98.83 %
-99.89 %
-99.73 %

Q-Linea operates in the medical technology sector. The company specializes in research and development of instruments and consumables. The products are mainly used in the treatment of infectious diseases and blood poisoning, and include diagnostic and analytical tools, as well as basic sample handling. The technology is based on the so-called ID and AST technology. Q-Linea was founded in 2008 and is headquartered in Uppsala.

Read more
Market cap
456.58M SEK
Turnover
95.53K SEK
Revenue
2.36M
EBIT %
-9,052.54 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.2
2026

Annual report '25

30.4
2026

Interim report Q1'26

27.5
2026

General meeting '26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release11/28/2025, 10:00 AM

New number of shares and votes in Q-linea AB (publ)

Q-Linea
Regulatory press release11/20/2025, 3:45 PM

Q-linea announces new organisation and changes in executive leadership team

Q-Linea
Press release11/18/2025, 12:05 PM

Q-linea announces FDA submission for expanded claims for ASTar® BC G- panel

Q-Linea

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/17/2025, 12:00 PM

Q-linea resolves to carry out a directed issue of shares to a guarantor in connection with the completed preferential rights issue

Q-Linea
Regulatory press release11/11/2025, 5:40 PM

Q-linea announces outcome of rights issue

Q-Linea
Regulatory press release10/22/2025, 12:30 PM

Q-linea publishes prospectus in connection with the rights issue

Q-Linea
Regulatory press release10/22/2025, 11:30 AM

Q-linea announces cost efficiency program to accelerate sales and marketing activities

Q-Linea
Regulatory press release10/21/2025, 3:00 PM

BULLETIN FROM Extraordinary GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-Linea
Press release10/21/2025, 8:26 AM

Redeye: Q-linea (Q3 Review) - Sales under expectations but solid cost control

Q-Linea
Q-Linea, Audiocast, Q3'25
Webcast10/20/2025, 11:00 AM

Q-Linea, Audiocast, Q3'25

Q-Linea
Regulatory press release10/20/2025, 5:30 AM

Interim report 1 January - 30 September 2025

Q-Linea
Regulatory press release10/19/2025, 6:55 PM

Stuart Gander appointed CEO and Anders Ljunggren appointed deputy CEO of Q-linea AB

Q-Linea
Press release10/3/2025, 8:00 AM

US Trauma Center signs commercial contract

Q-Linea
Regulatory press release9/18/2025, 6:10 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN Q-LINEA AB (PUBL)

Q-Linea
Press release9/18/2025, 6:05 AM

Q-linea | Letter from the CEO

Q-Linea
Regulatory press release9/18/2025, 6:00 AM

Q-linea resolves to carry out a rights issue of approximately SEK 322 million and announces terms

Q-Linea
Regulatory press release9/10/2025, 5:51 PM

Update on ESTAR tender for rapid AST

Q-Linea
Press release9/5/2025, 8:00 AM

Q-linea to initiate new clinical evaluations of ASTar in the GCC region

Q-Linea
Regulatory press release7/31/2025, 6:30 AM

New number of shares and votes in Q-linea AB (publ)

Q-Linea
Press release7/29/2025, 2:00 PM

BLASTID and Q-linea announce collaboration and conference presentation

Q-Linea
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.